explore -WSS

explore

author：explore 2025-09-30 14:58:58 - browse：8362

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Chimpanzees, like humans and whales, get menopause: Study

knowledge

Wikipedia

WSS

Physician subsidies by hospitals soar in wake of No Surprises Act

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Kenai launches with $82 million for Parkinson’s stem cell therapy

Scientists unlock the key to scar

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Telehealth options flood the market as retailers push virtual care

focus

explore

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Flu vaccine offering decent levels of protection this winter, new data show

Sports medicine is finally prioritizing gender equality

FogPharma raises $145 million in rare Series E round

New air purifier tech could be key to improving indoor air quality

Why Sanofi got shellacked over its spinoff

Anesthesiologist group: stop taking Ozempic before surgery

Obesity now affects over 1 billion people worldwide, study finds

At least 13 dead in Texas as scorching temps continue

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

knowledge

Cassava reveals details — and problems — with Alzheimer's study

Paying for Covid pills will soon shift to insurers

An inside look at PIPEs, biotech's buzzy new financing tool

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Physician subsidies by hospitals soar in wake of No Surprises Act

Traditional Chinese medicine benefits explored in new JAMA study

knowledge

Wikipedia

entertainment

explore